ArticleDiscover oncology2025
Impact of magnetic resonance imaging-defined sarcopenia on prognosis in patients with locally advanced nasopharyngeal carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic value of sarcopenia in patients with nasopharyngeal carcinoma: a meta-analysis.Annals of medicine · 2025Pooled it
- Prognostic impact of MRI-based cervical skeletal muscle mass on survival in parotid gland carcinoma.Japanese journal of clinical oncology · 2026Article
- Mendelian randomization analysis reveals potential association between allergic rhinitis and nasopharyngeal carcinoma.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo investigate the impact of sarcopenia assessed by pretherapy magnetic resonance imaging (MRI) of the third cervical vertebra (C3) on the survival of patients with locally advanced nasopharyngeal carcinoma (LANPC).
methodsWe analyzed the clinical information of 478 patients with LANPC who underwent radiotherapy between July 2016 and June 2019. Sarcopenia was evaluated using the skeletal muscle mass index, which was determined based on an MRI of the C3. The cutoff values for sarcopenia were determined using receiver operating characteristic curves. The thresholds were < 12.83 cm
resultsThe 5-year overall survival (OS) rate was 75.3%, with a median follow-up period of 59 months. Patients with sarcopenia (181/478) had a lower OS than those without sarcopenia (70.7% vs 78.1%, hazard ratio = 1.87, 95% confidence interval: 1.26-2.77, P < 0.01). Sarcopenia was elevated in patients with advanced T-stage tumors and a low body mass index. Univariate and multivariate analyses showed that sarcopenia, age, sex, T stage, and N stage were significant variables that affected the OS of patients with LANPC (P < 0.05).
conclusionsMRI-based sarcopenia is significantly correlated with the OS of patients with LANPC. This finding highlights the importance of evaluating sarcopenia before treatment, as it can guide personalized treatment programs, thereby enhancing patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.